CEO Andy Doraiswamy and CFO Damian Rippole will represent the Dallas-based firm, focusing their discussions on the Dayspring non-pneumatic compression treatment. The device, designed for patients managing chronic edema, serves as the cornerstone of the company’s current commercial strategy. Beyond the existing product line, the leadership team intends to update stakeholders on the status of their broader vascular pipeline and ongoing clinical investigations. Since its founding in 2018, Koya Medical has focused on developing evidence-based therapies intended to refine clinical outcomes for patients suffering from vascular diseases.
Koya Medical to Showcase Vascular Portfolio at BofA Healthcare Conference
Koya Medical will take its vascular treatment platform to the BofA Healthcare Trailblazers Private Company Conference in Boston on September 23, 2026. Executives plan to leverage the private forum to detail the company’s commercial expansion and current clinical research efforts following a period of steady growth in the sector.
Comments (0)
No comments yet. Be the first!